Patents by Inventor Benjamin R. LaFentz

Benjamin R. LaFentz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8420072
    Abstract: Vibrio vulnificus can cause infections in aquaculture-raised fish and is considered an opportunistic human pathogen. We isolated V. vulnificus from diseased hybrid tilapia (Oreochromis niloticus X O. aureus) cultured in a North American water reuse aquaculture facility. We have characterized the isolate using biochemical and molecular methods, developed a disease infection model, and determined that formalin-inactivated whole-cell vaccine provides protection against V. vulnificus. The V. vulnificus isolate was determined to be biotype 1, 16S rRNA type B, vcg type C, and vvhA type 2. Fish vaccinated with the formalin-inactivated whole-cell vaccine responded to vaccination as measured by agglutinating antibody titer. In two separate trials, vaccinated tilapia exhibited relative percent survival of 73 and 60% following challenge with the homologous isolate. In additional trials, vaccinated tilapia exhibited survival values of up to 87.5% following challenge with a heterologous isolate.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: April 16, 2013
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Craig A. Shoemaker, Benjamin R. LaFentz
  • Publication number: 20120244190
    Abstract: Vibrio vulnificus can cause infections in aquaculture-raised fish and is considered an opportunistic human pathogen. We isolated V. vulnificus from diseased hybrid tilapia (Oreochromis niloticus X O. aureus) cultured in a North American water reuse aquaculture facility. We have characterized the isolate using biochemical and molecular methods, developed a disease infection model, and determined that formalin-inactivated whole-cell vaccine provides protection against V. vulnificus. The V. vulnificus isolate was determined to be biotype 1, 16S rRNA type B, vcg type C, and vvhA type 2. Fish vaccinated with the formalin-inactivated whole-cell vaccine responded to vaccination as measured by agglutinating antibody titer. In two separate trials, vaccinated tilapia exhibited relative percent survival of 73 and 60% following challenge with the homologous isolate. In additional trials, vaccinated tilapia exhibited survival values of up to 87.5% following challenge with a heterologous isolate.
    Type: Application
    Filed: March 24, 2011
    Publication date: September 27, 2012
    Inventors: Craig A. Shoemaker, Benjamin R. LaFentz